Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.
Mazzaferro
V
V
Department of Surgery, Pathology, Immunohematology, National Cancer Institute, Milan, Italy.
Regalia
E
E
Pulvirenti
A
A
Tagger
A
A
Andreola
S
S
Pasquali
M
M
Baratti
D
D
Romano
F
F
Palazzo
U
U
Zuin
M
M
Bonino
F
F
Ribero
M L
ML
Gennari
L
L
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000401:mortality / Q000517:prevention & control* / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin